U.S. regulators on Tuesday approved a COVID-19 booster for people 50 or older, a measure that will provide additional protection for those most vulnerable to coronavirus rebounds.
The Food and Drug Administration plans to release a fourth Pfizer or Moderna drug to those people about four months after their first booster.
To date, the FDA has cleared up four of the 12 patients and the elderly who are particularly weak in immune systems. The agency said this fragile group could get a new booster, the hand shot.
The increase, regardless of public health, will allow for a new shot at millions of Americans – and the question of whether everyone will rush to get it. The Centers for Disease Control and Prevention is expected to weigh in.
Movement comes at a time of uncertainty. COVID-19 cases fell to low levels following the rise of the super-contagious Omicron species. Two vaccines and a booster are routinely given to provide strong protection against serious illness and death, CDC data show.
But an Omicron brother is responsible for the fearful surge of diseases in Europe – and spread to the US – even though the disease is still under control. About two -thirds of Americans have full treatment, and half of those who qualify for initial treatment do not receive it.
Pfizer has asked the FDA to clean up four shots for people 65 and older, while Moderna has asked for a new vaccine for all banks to “give it easier” for the government to decide on the ban. necessary.
There is little evidence to tell how much benefit a booster can provide right now. The FDA decided without input from its independent panel of experts who struggled with the amount of data needed to enhance the images.
“There may be a reason to raise the bar a little bit” for the elderly and those with other health conditions, said University of Pennsylvania immunologist E. John Wherry, who did not participate in the government.
But while he encourages old friends and family to follow the advice, the 50 -year -old Wherry – who is healthy, stable and empowered – doesn’t plan to take immediate action. four shots. In the face of serious illness he always said, “I’ll wait and see if it’s okay.”
None of the COVID-19 drugs were as potent against the Omicron mutant as they were against the early stages of the disease. In addition, the prevention of common diseases is significantly lower over time. But the immune system builds up many parts of the immune system and maintains the ability to prevent serious illness and death.
During the U.S. Omicron wave, two components were nearly 80% effective against ventilator efficiency or death – and the developer boosted that resistance to 94%, the CDC reported. . The lowest effect of the drug – 74% – was in immune -compromised people, most of whom did not receive a third.
U.S. health officials also monitored Israel, when the Omicron surge opened a fourth of the number to 60 people or more about four months after their last shot. The first data released online last week was thought to be an advantage: Israeli researchers estimated 92 deaths among the 328,000 people who received the maximum shot, compared. with 232 deaths among 234,000 people released in the fourth quarter.
The longer you get the new benefits from another booster, the longer it takes to get them.
“’When’ is a difficult part. Ideally, we’ll spend more time before the climb but we don’t know what the future holds, ”said Dr. William Moss of the Johns Hopkins Bloomberg School of Health.
In addition, the longer the distance between the images helps the shielding system to put on a stronger shield and be more cross-reactive.
“If you have a motivator close by, it doesn’t do any harm – you’re not going to get much benefit from it,” Wherry said.
The increase may not be the last: Next week, the government will hold a public meeting to discuss whether everyone should have a fourth, or a fall, the first crop or a second crop. shoot again.
In order to improve the medicinal properties, research is still being done on people – only Omicron -recorded images are combined with the original vaccine. The National Institutes of Health re -tested the monkeys and found “no significant benefit” in using a stimulant to bind only Omicron.
Must Read Stories from TIME